5-HT7 Receptors Are Involved in Neurogenic Dural Vasodilatation in an Experimental Model of Migraine

Journal of Molecular Neuroscience

Volumn 54, Issue 2, 2014, Pages 164-170

  Wang, Xiaojuan ^a   Fang, Yannan ^b   Liang, Jianbo ^b   Yan, Miansheng ^b   Hu, Rong ^a   Pan, Xiaoping ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Middle meningeal artery; Migraine; Neurogenic dural vasodilation; Serotonin 5 HT7 receptor

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; PHENOL DERIVATIVE; SEROTONIN 7 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SULFONAMIDE; SUMATRIPTAN;

ANIMAL; DURA MATER; MALE; MENINGEAL ARTERY; METABOLISM; MIGRAINE; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; TRIGEMINAL NERVE; VASCULARIZATION; VASODILATATION;

ANIMALS; DURA MATER; MALE; MENINGEAL ARTERIES; MIGRAINE DISORDERS; PHENOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SULFONAMIDES; SUMATRIPTAN; TRIGEMINAL NERVE; VASODILATION;

EID: 84894428205     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-014-0268-9     Document Type: Article

References (33)

1. Akerman S, Williamson DJ, Hill RG, Goadsby PJ (2001) The effect of adrenergic compounds on neurogenic dural vasodilatation. Eur J Pharmacol 424:53–58
2. Andreou AP, Holland PR, Goadsby PJ (2009) Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br J Pharmacol 157:464–473
3. Bourson A, Kapps V, Zwingelstein C, Rudler A, Boess FG, Sleight AJ (1997) Correlation between 5-HT7 receptor affinity and protection against sound-induced seizures in DBA/2 J mice. Naunyn-Schmiedeberg’s Arch Pharmacol 356:820–826
4. Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A et al (2009) 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. Pain 141:239–247
5. De Vries P, Sanchez-Lopez A, Centurion D, Heiligers JP, Saxena PR, Villalón CM (1998) The canine external carotid vasoconstrictor 5-HT1 receptor: blockade by 5-HT1B (SB224289), but not by 5-HT1D (BRL15572) receptor antagonists. Eur J Pharmacol 362:69–72
6. De Vries P, Willems EW, Heiligers JP, Villalón CM, Saxena PR (1999) Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses. Br J Pharmacol 127:405–412
7. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668–1675
8. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine—current understanding and treatment. N Engl J Med 346:257–270
9. Graf M, Jakus R, Kantor S, Levay G, Bagdy G (2004) Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy. Neurosci Lett 359:45–48
10. Hargreaves R (2007) New migraine and pain research. Headache 47:S26–S43
11. Hedlund PB, Sutcliffe JG (2004) Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 25:481–486
12. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG (2005) 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol Psychiatry 58:831–837
13. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115–2123
14. Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533–554
15. Kobe F, Guseva D, Jensen TP, Wirth A, Renner U, Hess D et al (2012) 5-HT7R/G12 signaling regulates neuronal morphology and function in an age-dependent manner. J Neurosci 32:2915–2930
16. Kurosawa M, Messlinger K, Pawlak M, Schmidt RF (1995) Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide. Br J Pharmacol 114:1397–1402
17. Lipton RB, Bigal ME (2008) Toward an epidemiology of refractory migraine: current knowledge and issues for future research. Headache 48:791–798
18. Mahé C, Loetscher E, Dev KK, Bobirnac I, Otten U, Schoeffter P (2005) Serotonin 5-HT7 receptors coupled to induction of interleukin-6 in human microglial MC-3 cells. Neuropharmacology 49:40–47
19. Martín-Cora FJ, Pazos A (2004) Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H] mesulergine: comparison to other mammalian species. Br J Pharmacol 141:92–104
20. Nicoletti P, Trevisani M, Manconi M, Gatti R, De Siena G, Zagli G et al (2008) Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig. Cephalalgia 28:9–17
21. Pericić D, Svob Strac D (2007) The role of 5-HT7 receptors in the control of seizures. Brain Res 1141:48–55
22. Schmuck K, Ullmer C, Kalkman HO, Probst A, Lubbert H (1996) Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur J Neurosci 8:959–967
23. Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142:1171–1181
24. Tepper SJ, Rapoport AM, Sheftell FD (2002) Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 59:1084–1088
25. Terrón JA, Martínez-García E (2007) 5-HT7 receptor-mediated dilatation in the middle meningeal artery of anesthetized rats. Eur J Pharmacol 560:56–60
26. Terrón JA, Bouchelet I, Hamel E (2001) 5-HT7 receptor mRNA expression in human trigeminal ganglia. Neurosci Lett 302:9–12
27. Tröltzsch M, Denekas T, Messlinger K (2007) The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur J Pharmacol 562:103–110
28. Wang X, Fang Y, Liang J, Yin Z, Miao J, Luo N (2010) Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine. Headache 50:579–587
29. Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E (2006) Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51:578–586
30. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997) Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat–intravital microscope studies. Cephalalgia 17:525–531
31. Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ (2001a) The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol 133:1029–1034
32. Williamson DJ, Shepheard SL, Cook DA, Hargreaves RJ, Hill RG, Cumberbatch MJ (2001b) Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats. Br J Pharmacol 133:807–814
33. Yanarates O, Dogrul A, Yildirim V, Sahin A, Sizlan A, Seyrek M et al (2010) Spinal 5-HT7 receptors play an important role in the antinociceptive and antihyperalgesic effects of tramadol and its metabolite, O-Desmethyltramadol, via activation of descending serotonergic pathways. Anesthesiology 112:696–710